Wockhdart is locked in lower circuit of 10% at Rs 1,122 on concerns of flat growth in the current financial year 2013-14 (FY14).
The stock opened at Rs 1,250 and hit a high of Rs 1,263 on BSE. A combined 1.18 million shares have changed hands on the counter and there are pending sell orders for 73,978 shares on BSE and NSE at 1340 hours.
“The company expects a single digit growth and a marginal dip in Ebitda (earnings before interest, taxes, depreciation and amortisation) margin in FY14 because of the Food and Drug Administration (FDA) related issue,” Murtaza Khorakiwala, managing director, Wockhardt, said during a conference call of the company’s senior officials and analysts.
Meanwhile, the stock of pharmaceutical company has tanked 39% over the past nine trading sessions on reports that the company received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad.
Wockhardt said that it is taking all steps to address the concerns raised by USFDA and shall put all efforts to resolve the issue at the earliest.
The impact of the import alert on the revenues is estimated to be in the range of $100 million (approximately Rs 550 crore) on an annualised basis, it added.
The stock opened at Rs 1,250 and hit a high of Rs 1,263 on BSE. A combined 1.18 million shares have changed hands on the counter and there are pending sell orders for 73,978 shares on BSE and NSE at 1340 hours.
“The company expects a single digit growth and a marginal dip in Ebitda (earnings before interest, taxes, depreciation and amortisation) margin in FY14 because of the Food and Drug Administration (FDA) related issue,” Murtaza Khorakiwala, managing director, Wockhardt, said during a conference call of the company’s senior officials and analysts.
Meanwhile, the stock of pharmaceutical company has tanked 39% over the past nine trading sessions on reports that the company received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad.
Wockhardt said that it is taking all steps to address the concerns raised by USFDA and shall put all efforts to resolve the issue at the earliest.
The impact of the import alert on the revenues is estimated to be in the range of $100 million (approximately Rs 550 crore) on an annualised basis, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%